BioSpace News Archive

OncoImmune, Inc. initiated its Phase III clinical trial testing the safety and efficacy of CD24Fc in hospitalized COVID-19 patients at the University of Maryland Baltimore Medical Center on April 20, 2020.

Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, announced it granted options to Brian Pereira, M.D., the newly-appointed Executive Chairman of the Company, to purchase 930,000 shares of Abeona common stock.

Statewide assessment will help prioritize those who need COVID-19 tests, schedule test appointments, and manage the spread of the virus

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported positive performance data for its SARS-CoV-2 antibody test.

Patients ages 70 years or younger who were new to CLL treatment lived longer without disease progression with the IMBRUVICA®-based regimen compared to patients treated with a chemoimmunotherapy regimen

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, announced it will report financial results for the first quarter 2020 after market close on Tuesday, May 12, 2020.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 first quarter financial results on Tuesday, May 5, 2020, after the close of the financial markets.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020 after the markets close.

—The American Association of Nurse Anesthetists is one of seven organizations to endorse a statement on the pivotal role advanced practice registered nurses are playing in the care of patients during the COVID-19 pandemic.

Cutera, Inc. announced the closing of its previously announced underwritten public offering of 2,742,750 shares of its common stock at a public offering price of $10.50 per share, which includes the exercise in full of the underwriter’s option to purchase up to an additional 357,750 shares of its common stock at the same price per share to cover over-allotments.